A new study supports a link between obstructive sleep apnea and increased risk for Parkinson’s disease and suggests early use ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Addressing these disparities requires the ability to process vast and noisy data efficiently—something that AI is uniquely ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug ...

“Central Vermont Medical Center has achieved the highest level of pediatric emergency readiness in Vermont through its participation in our statewide initiative,” said David Nelson, MD, a pediatric ...

R&D expenses for the year ended December 31, 2024 were $70.3 million, compared with $73.0 million for the same period of 2023 ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

The formula also stipulated that health risk allowance for clinical officers would be considered in the CBA, that MOH would “effect pending merit-based promotion, facilitate promotion as may be ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...